Evidence map›Paper›PMID 34148335›Full record

ArticleEuropean journal of translational myology2021

Evaluate the Therapeutic Effect of Allicin (L-cysteine) on Clinical Presentation and Prognosis in Patients with COVID-19.

Hosein Yaghoubian, Hossein Niktale, Arash Peivandi Yazdi, Vahideh Ghorani, Masoud Mahdavi Rashed, Amir Masoud Hashemian

Open access · goldAbstract read
In one paragraph

Article in European journal of translational myology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hosein YaghoubianDepartment of Emergency Medicine, Mashhad University of Medical Sciences, Mashhad. YaghoubianH1@mums.ac.ir.
Hossein NiktaleInnovation, Technology and Entrepreneurship, Molecule of allicin (L-cysteine) with Stabilized Oxidation Capacity, Mashhad. hoseen.nikta@gmail.com.
Arash Peivandi YazdiLung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad. peivandia@mums.ac.ir.
Vahideh GhoraniClinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad. GhoraniSV@mums.ac.ir.
Masoud Mahdavi RashedAkbar Children Hospital, Mashhad University of Medical Sciences, Mashhad. MahdaviRM@mums.ac.ir.
Amir Masoud HashemianDepartment of Emergency Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad. HashemianAM11@gmail.com.
Mashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The antiviral effectiveness of allicin (L-cysteine) has been shown by numerous studies in both levels of clinical and animals. The aim of this study was to evaluate the therapeutic effect of allicin (L-cysteine) on clinical presentation and prognosis. In the current study, 66 patients with COVID-19 based on clinical, radiological presentations and RT-PCR results, were enrolled in two groups of placebo and allicin. In the both allicin (L-cysteine) and placebo groups (n=33 in each group), the capsules were prescribed two times a day for two weeks. Clinical signs and symptoms, blood parameters and chest CT scan were evaluated before and two weeks after treatment. The results showed that allicin (L-cysteine) could significantly impact on improvement of signs and symptoms of COVID-19 after two weeks of treatment in comparison to placebo. Allicin (L-cysteine) not only improve the clinical signs, but also ameliorate the lab and radiological data, which suggest a therapeutic effect for this agent in COVID-19. Our data suggest the therapeutic effect of allicin (L-cysteine) on COVID-19 through improvement of clinical symptoms and acceleration of the healing process.

Identifiers

PMID34148335
PMCPMC8274222
OpenAlexW3173466022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.